Apogee Therapeutics, Inc. Closes Public Offering with Record Proceeds

Apogee Therapeutics, Inc. (Nasdaq: APGE) has successfully completed a public offering, raising a staggering $483 million in gross proceeds. The company, known for its innovative biologics targeting various inflammatory and immunology indications, saw strong demand for its shares, resulting in an upsized offering and full exercise of the underwriters' option to purchase additional shares. The closing of this offering marks a significant milestone for Apogee as it continues to advance its clinical-stage programs for conditions like atopic dermatitis and chronic obstructive pulmonary disease. With a focus on developing differentiated therapies to address unmet medical needs, Apogee is poised to make a meaningful impact in the healthcare industry. Investors and industry watchers are closely monitoring the company's progress as it works towards bringing its promising treatments to market.